Continuation Study for Latozinemab

Phase 3TerminatedNCT06111014

Alector Inc.17 enrolled

Overview

Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study

This is an open-label continuation study to provide access and assess the safety and tolerability of latozinemab in participants who have completed participation in their parent latozinemab study. All participants will receive open-label latozinemab at a dose of 60/mg/kg, every 4 weeks (q4w).

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Neurodegenerative Diseases

Interventions

LatozinemabDRUG

All participants will receive open-label latozinemab at a dose of 60/mg/kg, every 4 weeks

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Written informed consent must be obtained and documented (from the participant or, where jurisdictions allow it, from their legal decision maker). * Has successfully completed participation in their parent latozinemab study. * Female participants must be nonpregnant and nonlactating. * Male participants must agree to acceptable contraception use. Exclusion Criteria: * Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins. * Clinically significant heart disease, liver disease or kidney disease. History or evidence of clinically significant brain disease other than FTD.

Locations (18)

Dignity Health - Arizona

Phoenix, Arizona, United States

Mayo Comprehensive Cancer Center - PPDS

Rochester, Minnesota, United States